PROFOUND MEDICAL CORP(NASDAQ:PROF) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to PROF. PROF was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While PROF seems to be doing ok healthwise, there are quite some concerns on its profitability. PROF is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PROF has reported negative net income.

In the past year PROF has reported a negative cash flow from operations.

In the past 5 years PROF always reported negative net income.

In the past 5 years PROF always reported negative operating cash flow.

1.2 Ratios

PROF's Return On Assets of -39.06% is on the low side compared to the rest of the industry. PROF is outperformed by 61.78% of its industry peers.

Looking at the Return On Equity, with a value of -45.40%, PROF is in line with its industry, outperforming 51.31% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-39.06%
ROE	-45.4%
ROIC	N/A

ROA(3y)-49.72%

ROA(5y)-41.04%

ROE(3y)-64.26%

ROE(5y)-50.62%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PROF's Gross Margin of 66.72% is fine compared to the rest of the industry. PROF outperforms 70.68% of its industry peers.

PROF's Gross Margin has improved in the last couple of years.

PROF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	66.72%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y15.33%

GM growth 5Y2.85%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.

PROF has more shares outstanding than it did 1 year ago.

The number of shares outstanding for PROF has been increased compared to 5 years ago.

The debt/assets ratio for PROF has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.18 indicates that PROF is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 3.18, PROF is in the better half of the industry, outperforming 72.77% of the companies in the same industry.

PROF has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.

PROF has a better Debt to Equity ratio (0.05) than 64.40% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Altman-Z	3.18

ROIC/WACCN/A

WACC7.75%

2.3 Liquidity

A Current Ratio of 10.52 indicates that PROF has no problem at all paying its short term obligations.

With an excellent Current ratio value of 10.52, PROF belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.

A Quick Ratio of 9.64 indicates that PROF has no problem at all paying its short term obligations.

PROF has a better Quick ratio (9.64) than 92.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.52
Quick Ratio	9.64

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.04% over the past year.

Looking at the last year, PROF shows a very strong growth in Revenue. The Revenue has grown by 54.90%.

The Revenue has been growing by 20.67% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)17.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%52.38%

Revenue 1Y (TTM)54.9%

Revenue growth 3Y15.83%

Revenue growth 5Y20.67%

Sales Q2Q%107.91%

3.2 Future

Based on estimates for the next years, PROF will show a very strong growth in Earnings Per Share. The EPS will grow by 36.68% on average per year.

The Revenue is expected to grow by 78.52% on average over the next years. This is a very strong growth

EPS Next Y-0.1%

EPS Next 2Y10.45%

EPS Next 3Y-0.93%

EPS Next 5Y36.68%

Revenue Next Year151.33%

Revenue Next 2Y122.48%

Revenue Next 3Y101.92%

Revenue Next 5Y78.52%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PROF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PROF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.45%

EPS Next 3Y-0.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PROF!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROFOUND MEDICAL CORP

NASDAQ:PROF (4/22/2025, 8:00:00 PM)

4.67

+0.11 (+2.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)03-06 2025-03-06/amc

Earnings (Next)05-08 2025-05-08/amc

Inst Owners50.32%

Inst Owner Change0.01%

Ins Owners7.71%

Ins Owner Change0%

Market Cap140.29M

Analysts83.33

Price Target17.56 (276.02%)

Short Float %1.77%

Short Ratio6.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)7.13%

Min EPS beat(2)-28.63%

Max EPS beat(2)42.88%

EPS beat(4)3

Avg EPS beat(4)6.43%

Min EPS beat(4)-28.63%

Max EPS beat(4)42.88%

EPS beat(8)6

Avg EPS beat(8)4.17%

EPS beat(12)9

Avg EPS beat(12)7.41%

EPS beat(16)9

Avg EPS beat(16)-1.57%

Revenue beat(2)0

Avg Revenue beat(2)-2.87%

Min Revenue beat(2)-3.06%

Max Revenue beat(2)-2.68%

Revenue beat(4)0

Avg Revenue beat(4)-11.41%

Min Revenue beat(4)-32.27%

Max Revenue beat(4)-2.68%

Revenue beat(8)1

Avg Revenue beat(8)-13.11%

Revenue beat(12)2

Avg Revenue beat(12)-16.44%

Revenue beat(16)3

Avg Revenue beat(16)-21.8%

PT rev (1m)0.61%

PT rev (3m)18.44%

EPS NQ rev (1m)2.33%

EPS NQ rev (3m)-3.7%

EPS NY rev (1m)-23.68%

EPS NY rev (3m)-22.25%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-48.53%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-4.18%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	12.58
P/FCF	N/A
P/OCF	N/A
P/B	2.32
P/tB	2.33
EV/EBITDA	N/A

EPS(TTM)-1.12

EYN/A

EPS(NY)-1.12

Fwd EYN/A

FCF(TTM)-0.78

FCFYN/A

OCF(TTM)-0.78

OCFYN/A

SpS0.37

BVpS2.01

TBVpS2

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.06%
ROE	-45.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	66.72%
FCFM	N/A

ROA(3y)-49.72%

ROA(5y)-41.04%

ROE(3y)-64.26%

ROE(5y)-50.62%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y15.33%

GM growth 5Y2.85%

F-Score5

Asset Turnover0.16

Health

		Industry Rank	Sector Rank
Debt/Equity	0.05
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	10.52
Quick Ratio	9.64
Altman-Z	3.18

F-Score5

WACC7.75%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)17.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%52.38%

EPS Next Y-0.1%

EPS Next 2Y10.45%

EPS Next 3Y-0.93%

EPS Next 5Y36.68%

Revenue 1Y (TTM)54.9%

Revenue growth 3Y15.83%

Revenue growth 5Y20.67%

Sales Q2Q%107.91%

Revenue Next Year151.33%

Revenue Next 2Y122.48%

Revenue Next 3Y101.92%

Revenue Next 5Y78.52%

EBIT growth 1Y-14.16%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year13.92%

EBIT Next 3Y8.79%

EBIT Next 5Y39.35%

FCF growth 1Y-5.18%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-5.18%

OCF growth 3YN/A

OCF growth 5YN/A

PROFOUND MEDICAL CORP (PROF) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens